Technology Bundle ID
TAB-2773

Diagnostic Antigens for the Identification of Latent Tuberculosis Infection

Linked ID
E-249-2013-1
Lead Inventors
Frederick Quinn (CDC)
Co-Inventors
Kristin Birkness (CDC)
Manon Deslauriers (CDC)
Peter King (CDC)
Development Stages
Pre-clinical (in vivo)
Development Status
  • In vitro data available
  • In vivo data available (human)
ICs
CDC
CDC researchers have developed technology for sero-diagnosis of typically symptomless latent stage tuberculosis disease, posing a threat to individuals under immunosuppressive or anti-inflammatory therapies. Specifically, this diagnostic approach exploits M. tuberculosis secreted latency specific antigens, such as alpha-crystallin, in the blood or urine of patients. This type of test could easily be developed into an inexpensive dip-stick format with high specificity (no cross-reactivity with other mycobacteria), rapidity, and sensitivity (fewer bacteria needed for a positive identification). Because secreted antigens are recognized more readily by the immune system, serum-derived antibodies to these antigens can correspondingly be used for diagnostic or research use.
Commercial Applications
  • Development of a latent tuberculosis diagnostic
  • Improvements to current diagnostics
  • Public health/tuberculosis monitoring programs
  • Screening elderly patients before beginning anti-inflammatory and/or anti-arthritis therapy
Competitive Advantages
  • Rapid and inexpensive diagnostic for latent stage tuberculosis
  • Specific for latent form, unlike current IGRA/TST diagnostics
  • Easily developed as a cost effective dip-stick test
  • Provides high specificity (no cross-reactivity with other mycobacteria) and sensitivity (fewer bacteria needed for a positive identification)

Request More Info

Licensing Contact: